52 / 116
Time (months)
Progression-Free Survival, %
0
10
20
30
40
50
60
70
80
90
100
0 4 8 12 16 20 24 28 32 36 40 44
Median PFS in months (95% CI)
COMBO450
ENCO300
14.9 (11.0–20.2)
9.6 (7.4–14.8)
HR (95% CI), 0.77 (0.59–1.00)
Nominal 2-sided
P
=0.0498
Progression-Free Survival, %
0
10
20
30
40
50
60
70
80
90
100
Time (months)
0 4 8 12 16 20 24 28 32 36 40 44
COMBO450
ENCO300
Censored patients
ENCO300
VEM
Censored patients
Median PFS in months (95% CI)
ENCO300
VEM
9.6 (7.4–14.8)
7.3 (5.6–7.9)
HR (95% CI), 0.68 (0.52–0.88)
Nominal 2-sided
P
=0.0038
Reinhard Dummer
Abstract 9504. Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus
binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma
R Dummer